Type 1 diabetes: the new era of "islands of hope"

Type 1 diabetes is an autoimmune disease in which the immune system destroys the beta cells of the pancreas, responsible for producing insulin. For those affected, daily life is marked by constant blood glucose checks and insulin administrations.

But a new frontier of medicine could radically change this scenario.

A study published in the New England Journal of Medicine in 2025 demonstrated the possibility of restoring lost function through the transplantation of stem cells transformed into functioning pancreatic islets.

The challenge was enormous: to guide pluripotent stem cells to become highly specialized cells, capable of behaving like true beta cells. Clinical results indicate that this goal has been achieved. Once transplanted, these cells are able to detect blood glucose levels and release the amount of insulin necessary in real time.

In other words, the body returns to doing what it had stopped doing.

The change is above all conceptual. It is no longer about managing the disease with external tools, but about restoring an internal biological function. The patient is no longer forced to "control" their metabolism: they can live it again.

However, a crucial challenge remains. The new cells risk being recognized and destroyed by the immune system, just like the originals. Traditionally, this problem is addressed with anti-rejection drugs, which however entail significant side effects.

This is where genetic editing comes into play. By modifying the transplanted cells to make them less visible to the immune system, researchers aim to create stable and durable grafts, without the need for chronic immunosuppression.

It is an ambitious vision: a medicine that not only replaces what has been lost, but actively protects it from within. A medicine that increasingly aims to restore the body's natural balance instead of merely compensating for its deficiencies.

Editorial written by professor Antonio Giordano for “Medicina gli Highlights” - column published in Il Mattino.